Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular condition. It is the leading cause of sudden ...

The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date ...

Methods: Members of the Hypertrophic Cardiomyopathy Association ... demographic and self-reported clinical information, and types and triggers of symptoms. Respondents reported physical and ...

Aficamten is a small molecule cardiac myosin inhibitor designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle.

Favorable short- and long-term outcomes are seen in patients with hypertrophic cardiomyopathy who receive septal reduction therapy.

PDUFA Target Action Date Set for September 26, 2025SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ...

Objective Current guidelines recommend precautionary disqualification from competitive sports in patients with hypertrophic cardiomyopathy (HCM ... gender balance, symptoms, ECG abnormalities, extent ...

Because the data were obtained by anonymous self-reported survey, symptoms cannot be correlated with clinical data. These data should be considered as hypothesis-generating, and prospective ...

“That used to be true, but there have been huge advances in clinical care ... with obstructive forms of hypertrophic ...